GlaxoSmithKline launches 2 new innovative vaccines

7160 Investors following GlaxoSmithKline. Share this News with them.

0

Like this story, share it with millions of investors on M3

GlaxoSmithKline launches 2 new innovative vaccines

GlaxoSmithKline launches 2 new innovative vaccines, Launches New DTP Vaccines with Acellular Technology- Boostrix to prevent waning immunity against Diphtheria, Tetanus & Pertussis in older children and adolescents Infanrix for childhood DTP immunization, offers reduced pain, fever and swelling

Post your opinion here

 

0

Tweet

Share on Tumblr

RELATED NEWS GSK doubles clinical trials GlaxoSmithKline Pharma top gainer on the Nifty GlaxoSmithKline launches ActiBase ALSO READ See latest News about GlaxoSmithKline See previous management interviews See what other Experts & Brokerages are saying about GlaxoSmithKline GlaxoSmithKline BSE | NSE 25/05/12 Are Mutual Funds betting on GlaxoSmithKline?

GlaxoSmithKline Pharmaceuticals Ltd . (GSK), today announced the launch of two new innovative Diphtheria, Tetanus and acellular Pertussis (DTP) vaccines- Boostrix and Infanrix. Unlike traditional vaccines, acellular vaccines provide far more comfort to parents and the children due to substantially reduced pain, fever and swelling. Worldwide, acellular DTP vaccines are a part of routine immunization in over 100 developed and developing countries.

Infanrix is indicated for childhood immunization against Diphtheria, Tetanus and Pertussis for newborns from 6^th week of age. When combined with Hib vaccines it reduces the number of pricks and visits to the doctor.

Boostrix can be administered to older children above 7 years of age, adolescents and adults and will boost the waning immunity against Diphtheria, Tetanus and Pertussis. Studies have shown that immunity against Diphtheria, Tetanus and Pertussis wanes after childhood immunization as protection lasts up to 4-12 years after vaccination. Due to waning immunity, incidence of pertussis and diphtheria is increasing in adolescents and adults. Of concern is the fact that adults can pass Pertussis infection to infants leading to high disease burden. Till date there was no vaccine available in India, which could be given to this age group.

GSK's Boostrix is USFDA approved and well accepted in 58 countries. American Academy of Pediatrics (AAP) recommends Boostrix at 10 years of age.

Commenting on the launch of the two vaccines, Dr. Hasit Joshipura, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said, "GSK India remains committed to providing the latest and most effective preventive care particularly for children. The launch of Infanrix and Boostrix will be a step forward in this mission."

Sourced From: Adfactors Public Relations Pvt Ltd